24 HR divalproex sodium 500 MG Extended Release Oral Tablet [Depakote]
divalproex sodium
RxCUI: 1099571
What the CMS Formulary Data Shows for 24 HR divalproex sodium 500 MG Extended Release Oral Tablet [Depakote]
Per the CMS 2026 Part D formulary file, 24 HR divalproex sodium 500 MG Extended Release Oral Tablet [Depakote] (RxNorm concept RXCUI 1099571, generic name divalproex sodium) appears on 2 distinct formulary files spanning 8 Medicare Part D plan offerings - 0.2% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.5.
Real-world access to 24 HR divalproex sodium 500 MG Extended Release Oral Tablet [Depakote] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 113 Part D beneficiaries filled 24 HR divalproex sodium 500 MG Extended Release Oral Tablet [Depakote] in 2023, with total plan-and-beneficiary spending of $276,969 and an average per-beneficiary annual cost of $2,451.05. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 24 HR divalproex sodium 500 MG Extended Release Oral Tablet [Depakote] today.
Coverage Details
- Formularies covering
- 2
- Plans covering
- 8
- Coverage rate
- 0.2%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 113
- Total spending
- $276,969
- Avg per beneficiary
- $2,451.05
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering 24 HR divalproex sodium 500 MG Extended Release Oral Tablet [Depakote]
8 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Hamaspik Medicare Choice (HMO D-SNP) | HAMASPIK, INC. | T1 | No | $0 | NY |
| Hamaspik Medicare Select (HMO D-SNP) | HAMASPIK, INC. | T1 | No | $34.50 | NY |
| Óptimo Plus (PPO) | TRIPLE S ADVANTAGE, INC. | T4 | No | $0 | PR |
| Contigo Plus (HMO C-SNP) | TRIPLE S ADVANTAGE, INC. | T4 | No | $0 | PR |
| Brillante (HMO-POS) | TRIPLE S ADVANTAGE, INC. | T4 | No | $0 | PR |
| Enlace Plus (HMO) | TRIPLE S ADVANTAGE, INC. | T4 | No | $0 | PR |
| ContigoEnMente (HMO C-SNP) | TRIPLE S ADVANTAGE, INC. | T4 | No | $0 | PR |
| Ahorro Plus (HMO) | TRIPLE S ADVANTAGE, INC. | T4 | No | $0 | PR |
Frequently Asked Questions
Is 24 HR divalproex sodium 500 MG Extended Release Oral Tablet [Depakote] covered by Medicare Part D?
Yes, 24 HR divalproex sodium 500 MG Extended Release Oral Tablet [Depakote] is covered by 8 Medicare Part D plans (0.2% of all Part D formularies).
What tier is 24 HR divalproex sodium 500 MG Extended Release Oral Tablet [Depakote] on Medicare Part D plans?
24 HR divalproex sodium 500 MG Extended Release Oral Tablet [Depakote] averages Tier 2.5 across Part D plans, ranging from Tier 1 to Tier 4.
Does 24 HR divalproex sodium 500 MG Extended Release Oral Tablet [Depakote] require prior authorization?
0% of Part D formularies require prior authorization for 24 HR divalproex sodium 500 MG Extended Release Oral Tablet [Depakote]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on 24 HR divalproex sodium 500 MG Extended Release Oral Tablet [Depakote]?
In 2023, total Medicare Part D spending on 24 HR divalproex sodium 500 MG Extended Release Oral Tablet [Depakote] was $276,969, covering 113 beneficiaries. The average spend per beneficiary was $2,451.05.
Read our methodology - how this data is sourced, computed, and verified.